Cambodia

in page functions
[French]
Cambodia
Total population (2017) 16,076,335
Birth cohort (2017) 370,092
Surviving Infants (surviving to 1 year per year, 2017) 362,318
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 25/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 29/1000
World Bank Index, IDA (2015) 3.40
Gross Nation Income (per capita US$, 2015) 1,070
Co-financing group (2017) Preparatory transition
No. of districts/territories (2015) 92

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Cambodia

Type of support

Approvals

2001-2021 (US$)
(29 Jun 2017)

Commitments

2001-2021 (US$)
(29 Jun 2017)

Disbursements

2000-2017 (US$)
(29 Jun 2017)

% Disbursed

(29 Jun 2017)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Total $80,053,480 $96,422,114 $80,526,204
Cash Support (CASHSUPP) $191,500 $216,500 $191,500 100%
Health system strengthening (HSS 1) $10,315,500 $10,315,500 $10,315,500 100%
Health system strengthening (HSS 2) $7,738,914 $18,058,048 $7,738,914 100%
HPV Demo (NVS) $291,500 $291,500 $158,830 54%
Immunisation services support (ISS) $1,828,700 $2,007,200 $1,828,700 100%
Injection Safety Devices (NVS) $235,500 $343,500 $307,847 131%
Injection safety support (INS) $587,653 $587,653 $587,653 100%
IPV (NVS) $1,806,656 $1,806,656 $1,218,856 67%
JEV (NVS) $2,277,000 $2,277,000 $2,321,553 102%
JEV - Operational costs (OPC) $2,665,500 $2,665,500 $2,665,500 100%
Measles (NVS) $1,108,811 $1,108,811 $1,102,666 99%
Measles-Rubella (NVS) $3,435,509 $3,435,509 $3,435,509 100%
MR - Operational costs (OPC) $3,220,000 $3,220,000 $3,220,000 100%
MR-Follow-up campaign (NVS) $1,125,500 $1,125,500 $1,105,649 98%
MR-Follow-up campaign op.costs (OPC) $1,049,500 $1,049,500 $1,049,052 100%
Penta (NVS) $19,763,601 $21,591,101 $21,124,969 107%
Pneumo (NVS) $12,870,183 $16,780,683 $12,611,553 98%
Tetra DTP-HepB (NVS) $8,038,453 $8,038,453 $8,038,453 100%
Vaccine Introduction Grant (VIG) $1,503,500 $1,503,500 $1,503,500 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Cambodia DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2016)

Grade of confidence


N/A
DTP3 - Official country estimates (2016) 99%
M:F sex ratio at birth (2017) 1.05
Household survey: DTP3 coverage for male (2013) 83.00%
Household survey: DTP3 coverage for female (2013) 84.30%
Household survey: Last DTP3 survey (2013) 84%
% districts achieving > 80% DTP3 coverage (2015) 85%
% districts achieving < 50% DTP3 coverage (2015) 0%
MCV WHO/UNICEF estimates (2016) 81%

Breakdown of support

Non-vaccine support Vaccine support
36% 64%
$29,100,319 $51,425,885

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Cambodia

01 December 2015

Dagfinn Høybråten in Geneva 2015

'Deliver, deliver, deliver' – Dagfinn Høybråten reflects on five years as Gavi Board Chair

Dagfinn Høybråten will this week chair a Gavi Board meeting for the last time before stepping down at the end of the year. Here he reflects on five years at the helm of the Vaccine Alliance, steering Gavi through some of the momentous events in its 15-year history.

01 April 2015

Lao PDR to protect more than 1.5 million children from Japanese encephalitis

Lao PDR to protect more than 1.5 million children from Japanese encephalitis

Gavi supports national campaign to prevent mosquito-borne disease.

27 November 2013

Gavi Board meeting, 21-22 November 2013

The Gavi Board meeting was held in Phnom Penh, Cambodia on 21-22 November 2013. The current Vice Chair Geeta Rao Gupta was reappointed for a second two-year term.
 

Key decisions include the appointment of health ministers from Uganda and Guyana to represent Gavi-eligible countries, the Board Travel Policy, the opening of a funding window for the Japanese Encephalitis and Inactivated Polio vaccines and a new Vaccine Investment Strategy.

close icon

modal window here